NCT04898907

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

A Single Part, Four-Way Crossover, Randomized, Partially-Blinded Study to Evaluate the Effect of Intravenous ANG-3777 on Baseline-Adjusted QT/QTc Interval in the Fasted State in Healthy Male and Female Subjects

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Angion Biomedica Corp · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the effect of ANG-3777 on placebo-corrected change from baseline, QT/corrected QT (QTc) interval, following single intravenous (IV) doses in healthy volunteer adults.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	ANG-3777 (Therapeutic Dose)	Arms assigned to this intervention will receive 2 mg/kg, IV, Fasted
DRUG	ANG-3777 (Supra-therapeutic Dose)	Arms assigned to this intervention will receive 6 mg/kg, IV, Fasted
DRUG	Placebo	Arms assigned to this intervention will receive normal saline, IV, Fasted
DRUG	Moxifloxacin Hydrochloride	Arms assigned to this intervention will receive 400 mg, Oral, Fasted

Timeline

• Start date: 2021-06-01
• Primary completion: 2021-09-01
• Completion: 2021-09-01
• First posted: 2021-05-24
• Last updated: 2021-06-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study